You Should Know These Things About Biohaven Pharmaceutical Holding Company Ltd. (BHVN)

As of Friday close, Biohaven Pharmaceutical Holding Company Ltd.’s (NYSE:BHVN) stock was up $0.4, moving up 0.28 percent to $141.00. The average number of shares traded per day over the past five days has been 8,853,080 shares. 2 times new highs have been achieved over the past 5 days, with a $50.75 gain in that time frame. In the last twenty days, the average volume was 2,923,895, while in the previous 50 days, it was 1,516,164.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Since last month, BHVN stock rose 22.26%. Shares of the company fell to $79.01 on 04/29/22, the lowest level in the past month. A 52-week high of $151.51 was reached on 05/10/22 after having rallying from a 52-week low of $65.24. Since the beginning of this year, BHVN’s stock price has risen by 2.31% or $3.19, and marked a new high 3 times. However, the stock has declined by -6.94% since its 52-week high.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) last reported insider trading activity 4 days ago on May 10. Clark George C., the VP, Chief Accounting Officer of the company, disposed of 4,200 shares for $141.50 on May 10. It resulted in a $594,300 divestment by the insider. Clark George C. sold 9,375 shares at an average price of $117.01 on Jan 19. The insider now owns 6,015 shares following the transaction. On Dec 20, Director GREGORY JULIA P sold 12,000 shares at $125.00 apiece. The transaction was valued at $1,500,000.

Financial Health

In the three months ended September 29, Biohaven Pharmaceutical Holding Company Ltd.’s quick ratio stood at 1.50, while its current ratio was 1.60, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 80.20% percent. Based on annual data, BHVN earned $370.85 million in gross profit and brought in $462.51 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -168.90%. Return on equity (ROE) for the past 12 months was 164.60%.

In Biohaven Pharmaceutical Holding Company Ltd.’s quarter-end financial report for September 29, it reported total debt of $634.11 million against cash and short-term investments of $433.41 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. BHVN’s revenue rose 86.26% during the quarter, while net income inched up to $318.85 million. While analysts expected Biohaven Pharmaceutical Holding Company Ltd. to report -$2.4 quarterly earnings, the actual figure was -$2.63 per share, beating the consensus estimate by -9.60%. During the quarter, the company generated -$49.43 million in EBITDA. The liabilities of Biohaven Pharmaceutical Holding Company Ltd. were 1.84 billion at the end of its most recent quarter ended September 29, and its total debt was $826.1 million. The value of shareholders’ equity is $71.04 million.

Technical Picture

This quick technical analysis looks at Biohaven Pharmaceutical Holding Company Ltd.’s (BHVN) price momentum. With a historical volatility rate of 272.35%, the RSI 9-day stood at 72.74% on 13 May.

With respect to its five-day moving average, the current Biohaven Pharmaceutical Holding Company Ltd. price is up by +56.23% percent or $50.75. At present, BHVN shares trade +27.16% above its 20-day simple moving average and +8.47% percent above its 100-day simple moving average. However, the stock is currently trading approximately +21.74% above its SMA50 and +11.78% above its SMA200.

Stochastic coefficient K was 95.07% and Stochastic coefficient D was 85.68%, while ATR was 9.66. Given the Stochastic reading of 95.38% for the 14-day period, the RSI (14) reading has been calculated as 66.99%. As of today, the MACD Oscillator reading stands at 27.61, while the 14-day reading stands at 33.17.

Analyst Ratings

Biohaven Pharmaceutical Holding Company Ltd. downgraded its rating on Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) to a Mkt perform in a note to investors on May 11, 2022. The analysts firm previously had an Outperform rating on the stock.Biohaven Pharmaceutical Holding Company Ltd. (BHVN) has been rated Overweight by analysts. According to 0 brokerage firms, BHVN is a sell, and 4 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Biohaven Pharmaceutical Holding Company Ltd. stock as buy, with 6 recommending it as overweight.

With a median target price of $154.00, the current consensus forecast for the stock is $148.50 – $170.00. Based on these forecasts, analysts predict Biohaven Pharmaceutical Holding Company Ltd. (BHVN) will achieve an average price target of $156.28.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles